The topic is short and compact
An active ingredient trend only becomes a product when stability, packaging, and permissible claims are resolved together, not sequentially.
Antioxidants are the most technically demanding group because the exact reactivity that provides the benefit also causes the instability.
Sensory profile and particle control are formulation parameters with their own testing requirements and belong in the product specifications, not in communication.
A trend describes a demand, not a formulation. The request specifies an active principle, such as protection against oxidative stress or a gentler form of skin renewal. In development, the question then arises as to the concentration, the pH window, and the packaging in which this principle can survive at all over its entire shelf life.
The typical breaking points repeat themselves. The active ingredient is planned in a concentration that comes from a study and not from a marketable formulation. The packaging is selected according to design criteria and only then tested for light protection and oxygen permeability. The claim is formulated before it is clear what proof is available for it.
Weigh active concentration against stability and skin compatibility, do not maximize it.
Treat packaging as part of the formulation, not as a downstream design issue.
Clarify claims and verifiability parallel to development.
Define the sensory profile early on because it helps determine the basis of the formulation.
How a trend can be systematically checked for feasibility before development budget is committed is described in Trends auf Machbarkeit prüfen.
Why most active ingredient trends fail due to the formulation
A trend describes a demand, not a formulation. The request specifies an active principle, such as protection against oxidative stress or a gentler form of skin renewal. In development, the question then arises as to the concentration, the pH window, and the packaging in which this principle can survive at all over its entire shelf life.
The typical breaking points repeat themselves. The active ingredient is planned in a concentration that comes from a study and not from a marketable formulation. The packaging is selected according to design criteria and only then tested for light protection and oxygen permeability. The claim is formulated before it is clear what proof is available for it.
Weigh active concentration against stability and skin compatibility, do not maximize it.
Treat packaging as part of the formulation, not as a downstream design issue.
Clarify claims and verifiability parallel to development.
Define the sensory profile early on because it helps determine the basis of the formulation.
How a trend can be systematically checked for feasibility before development budget is committed is described in Trends auf Machbarkeit prüfen.
Antioxidants: the reactivity that creates the benefit also creates the problem
Antioxidants work because they easily donate electrons. It is precisely this property that makes them vulnerable in the formulation. They react with atmospheric oxygen, with traces of metal from raw materials and equipment, with light, and with an unfavorable pH value. A formulation that does not protect the active ingredient loses it on the shelf, long before the consumer empties the package.
Stabilization is therefore not an additive, but the core of development. It consists of several independent measures that work together: appropriate pH management, the exclusion of metal ions using complexing agents, reduced oxygen entry in the manufacturing process, a coordinated antioxidant system, as well as derivatives or encapsulated forms if the free form cannot be controlled.
Know the pH window of the active ingredient and align the formulation to it.
Use complexing agents because even traces of iron or copper accelerate degradation.
Limit oxygen entry through stirring speed, vacuum, and filling.
Check derivatives or encapsulation if the free form remains unstable.
Secure light protection and oxygen barrier via packaging and airless systems.
How an active ingredient strategy can be planned across a range instead of solving each formulation individually is shown in Wirkstoffstrategie, complementing the categorization of individual active ingredient classes in Peptide, PDRN und Niacinamid.
Mild exfoliation: The effect comes from the dosage, not the harshness
Demand is shifting from strong acid peels toward controlled, mild renewal. Technically, this does not mean less effort, but a different kind. For mechanical and particle-based systems, the particle size, particle shape, and above all, the uniform distribution throughout the entire batch and the entire shelf life are decisive.
The critical point is the suspension. If particles sink during storage or float to the top, the actual dose applied changes from the first to the last application. This is not just a quality issue, but a skin compatibility issue, because the concentration at the end of the tube can be significantly higher than at the beginning.
Adjust rheology so that particles remain permanently in suspension.
Specify particle size and edge shape and record them in the incoming inspection.
Check homogeneity at the beginning, middle, and end of the filling process.
Evaluate skin compatibility based on the real frequency of use, not on a single application.
Check enzymatic or polymer-based alternatives if particles put a strain on the packaging material.
Whether the adjusted suspension holds up over the shelf life is only revealed during the testing phase of the final formulation in the final packaging, see Stability and Safety Testing.
Sensory profile is a formulation parameter with its own testing effort
Consumers evaluate efficacy first through what they perceive immediately. A product whose benefit only becomes apparent after weeks therefore needs a sensory signal that supports the application. This signal does not arise in communication, but in the formulation: through the choice of emollients, absorption behavior, film formation, cooling, and afterfeel.
The clean separation between experience and efficacy claims is important. A tingling sensation or a cooling note may be described as a sensory characteristic. It must not be presented as proof of an effect for which there is no evidence. This separation protects against vulnerable claims and against expectations that the product does not fulfill.
Define the target sensory profile in writing before starting development.
Work with a fixed evaluation grid instead of individual opinions.
Evaluate the sensory profile again after the stability test, because it shifts.
Cleanly separate experience and efficacy statements in communication.
An overloaded target sensory profile is one of the most common reasons for additional development loops, as described in Overengineering vermeiden.
What may legally remain of an active ingredient trend
The more scientifically a trend is argued, the greater the temptation to directly advertise the mechanism of action. This is precisely where EU regulations set tight boundaries. What is permissible is what is proven for the finished product. Transferring a raw material study to the final product or making a claim that suggests a therapeutic effect is not permitted.
In practical terms, this means that claims regarding cell functions, repair, or regeneration are not sustainable without product-specific proof. Formulations that describe protection against environmental oxidative stress are possible depending on the level of evidence. The decision is made based on the demonstrable benefit, not on the plausibility of the mechanism of action.
Provide proof at the product level, not at the raw material level.
Have mechanistic formulations reviewed before packaging is printed.
Build up the supporting documentation parallel to development, not afterwards.
Which claims are viable under Regulation (EU) 655/2013 and which are regularly objected to is detailed in EU advertising claims.
Using leading indicators without following every signal
Many active ingredient and texture trends appear in Asian markets twelve to eighteen months earlier than in Europe. This lead time is a real planning advantage, but only if it is used as an observation window and not as a starting signal. A signal only becomes resilient when it persists across multiple brands and multiple seasons and is not due to a single viral effect.
The sensible way to handle this is a brief preliminary check before development capacity is tied up: Are the raw materials available in European quality and quantity, is the claim possible within the European framework, and does the category fit into the existing range. Only when these three questions are answered with yes is formulation development worthwhile.
Check signal stability across multiple brands and seasons.
Clarify raw material availability in European quality and quantity.
Assess the permissibility of the planned claim in advance.
Check assortment fit instead of building an isolated single innovation.
Which trends for 2026 can actually be implemented and which fail due to raw materials or regulations is classified in Trends 2026 and their feasibility.
Active ingredient-driven products are rarely the cheapest to develop. High-quality active ingredients, protective packaging and an increased scope of testing work together to affect the unit price. At the same time, the minimum quantities are often determined by the packaging material, such as in the case of airless systems with their own tooling, and not by the formulation.
For the schedule, the twelve-week accelerated stability test remains the fixed block on the critical path. In the case of oxidation-sensitive formulations, it cannot be shortened because this is precisely where the active ingredient content is proven over time. Six to nine months from the idea to the first batch are realistic, provided the packaging is determined early on.
Demand a binding statement on the stabilization strategy before start of development.
Request analysis of the active ingredient content over the term, not just sensory profile and optics.
Inquire about minimum quantities separately for formulation and packaging material.
Agree on a test plan in writing, including packaging compatibility.
As a B2B partner, Labtree develops and produces in this order: first feasibility and stabilization concept, then formulation in its own laboratory, then samples and testing. Basics on quantities and time in Minimum purchase quantities and Shorten time-to-market.
More useful links
FAQ
Why are antioxidant formulations technically so demanding?
Because the property that creates the benefit also causes the instability. Antioxidants readily donate electrons and therefore react with atmospheric oxygen, trace metals, light, and an unfavorable pH value. Stability is only achieved through a combination of several measures: pH control, complexing agents, reduced oxygen exposure, and if necessary, derivatives or encapsulation, along with packaging that provides a light and oxygen barrier.
What is the critical point in particle-based microexfoliation?
The permanent suspension. If particles settle or float to the top, the applied dose changes from the first to the last application, which is a skin compatibility risk. The rheology must therefore be adjusted so that the distribution remains stable over the entire shelf life, and the homogeneity should be tested at the beginning, in the middle, and at the end of the filling process.
Can a noticeable effect be advertised as an active benefit?
No, not without product-related proof. A tingling or cooling sensation may be described as a sensory characteristic. It may only serve as proof of an effect if this effect has been proven for the finished product. Separating the sensory experience from the promised effect protects against vulnerable claims.
Can an ingredient study serve as proof for the product claim?
As a rule, no. According to Regulation (EU) 655/2013, the evidence must support the finished product in its actual application. A study on the pure active ingredient in a high concentration cannot be transferred to a finished product with a different concentration and a different matrix. The proof should therefore be developed in parallel with the development process.
How long does it take to develop an active ingredient-driven product?
Realistically six to nine months from the idea to the first batch. The fixed block is the accelerated stability testing over twelve weeks, which cannot be shortened for oxidation-sensitive formulations, because that is where the active ingredient content is proven over time. What can be brought forward above all is the early determination of the packaging.
Is it worth following Asian trend signals?
As an observation window, yes; as a starting signal, no. The lead time is often twelve to eighteen months. A signal only becomes reliable when it persists across multiple brands and seasons. Before development, three questions should be clarified: raw material availability in European quality, admissibility of the claim within the European framework, and fit with the existing product range.
